Overview of Neuro20
Neuro20 was birthed from a single person trying to help himself and his military brothers and sisters and from this, a new science was brought to light when the world needs it more than ever. As the first portable treatment system that is cleared by the FDA for medical use and as a Durable Medical Equipment (DME) that is allowed to be dispensed to the home, Neuro20 is an innovative company that is creating solutions to tackle the most challenging health problems with safe, effective, and easy to use whole body electrical muscles stimulation.
Our Ask
Neuro20 is seeking indications of interest from potential funding sources to accelerate its growth and expand market presence. We are actively looking for strategic partners to support clinical trials, marketing initiatives, and participation in key expos and conferences. While we have successfully developed our technology and obtained FDA clearance, market education remains a priority. Accordingly, another goal is to partner with organizations to increase brand awareness and encourage adoption through clinical trials, targeted outreach, and strategic collaborations.
Product or Service
Neuro20 is a system, with whole-body Electrophysiological Neuromodulation Smart Suit that provides non-invasive, drug-free, and portable delivery of Functional Electrical Stimulation (FES) that is the equivalent to 20 smaller electrical devices all coordinated through a single delivery system controlled via an iPad to deliver a consistent and controllable electric dosage to provide therapeutic benefits to many medical related conditions.
Company Impact
In a world where chronic health conditions are rapidly rising, costs for care are out of control, and there are not enough medical providers to treat an aging and unhealthy population, the moment for innovation is now….and Neuro20 is here to meet healthcare where is needs to be met. Our tagline of “Technology That Moves You” is beyond just the physical. Neuro20 has shown benefits across many neurological, autonomic, chronic pain, and orthopedic conditions that is so profound, it is going to change the science books as this incredible innovation expands across the globe.
Primary Audience
Multiple Sclerosis, Amputees, Dysautonomic Conditions (Long Covid, POTS, ME/CFS), Chronic Pain, Parkinson’s, Spinal Cord Injury (SCI), Traumatic Brain Injury (TBI). Neuro20 biggest impact are where the conditions are life long / progressive processes that are very expensive and options to improve functionality and quality of life are very limited. Neuro20 is the scalable innovation we have been waiting for to hit these problems head on.
Partnership Opportunity
Neuro20 has established partnerships with top institutions including Shirley Ryan Ability Lab (#1 in Neurological Rehabilitation), Spaulding/Harvard (#2 – Starting Mid April), Brooks Rehabilitation (Has started first IRB for SCI/TBI), Johns Hopkins, Barrow Neurological Institute, Shepherd Center, University of Colorado Anschutz. Neuro20 best collaboration / partnerships are with the payors of healthcare, such as Veterans Administration, Government Healthcare, Self-Funded Employers, or Insurance Companies that are on the hook for these life long, expensive conditions to treat.